Key facts
- It has raised $4.9M; the latest was Equity Crowdfunding ($260K) in Jun 2024.
- Notable investors include The University of Tokyo Edge Capital, LINK-J, National Institute of Advanced Industrial Science and Technology, New Energy and Industrial Technology Development Organization.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Socium
- ·The full record, as it builds
Funding rounds
No funding rounds for Socium are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Socium
Operator of a clinical research company intended to facilitate drug discovery and development procedures. The company develops pharmaceuticals using a systems biology approach to omics data for drug-repositioning to find unexpected drugs against disease among the commercialized drugs, enabling the healthcare industry to identify and develop new uses for existing drugs.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2017
- Employees
- 10
- Website
- socium.co.jp/
- Ownership
- Privately Held (backing)
Socium doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Socium shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Socium in its N-PORT filings yet. We sweep new filings monthly.